Jun 10,2017

SCIENTIFIC STUDIES ADDRESSING BGMS AND CGM ACCURACY PRESENTED AT THE AMERICAN DIABETES ASSOCIATION'S 77TH SCIENTIFIC SESSIONS

This week at the American Diabetes Association 77th Scientific Sessions, data were presented from three studies that assessed the accuracy and analytical performance of blood glucose monitoring systems (BGMS) and continuous glucose monitoring (CGM) systems. Posters from two investigator initiated studies presented the accuracy data of various BGMS, while another poster, presented by Ascensia, described a new method for evaluating the analytical performance of CGM systems.

CLINICAL STUDY

#bgm

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 12,2017

Insulet Presents Positive Omnipod® Horizon™ Hybrid Closed-Loop Study Results in Children

Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced additional promising data from the first feasibility study of the Omnipod® Horizon™ Automated Glucose Control System (Omnipod Horizon) hybrid closed-loop system. Initial results presented earlier this year demonstrated Insulet's personalized model predictive control (MPC) algorithm performed well, was safe during the day and night for adults with type 1 diabetes, and was very effective at night with minimal hypoglycemia and excellent fasting glucose.

CLINICAL STUDY

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jun 12,2017

Nemaura Medical Inc. reports major improvement in sugarBEAT® sensor performance

Nemaura Medical Inc. (OTCBB: NMRD), a medical device company announced the latest version of the sensor component of it’s sugarBEAT® non-invasive wireless skin-patch has achieved a more than 300% improvement in glucose detection. This major improvement is expected to enhance sugarBEAT® accuracy as expressed through MARD, by enabling diabetics to better detect small fluctuations in glucose levels, and for sugarBEAT® to detect glucose at very low levels.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 12,2017

Tandem Diabetes Care Presents Findings from Predictive Low Glucose Suspend (PLGS) Feasibility Study and Announces Approval of Investigational Device Exemption (IDE) for Pivotal Trial

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today presented results from a feasibility study for its predictive low glucose suspend (PLGS) algorithm, designed to suspend insulin delivery when low blood sugar is predicted.

CLINICAL STUDY

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 21,2017

DarioHealth Looks to Accelerate Market Penetration with Expanded Health Insurance Coverage to Target up to 10 Million Consumers

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it is expanding its insurance coverage provider network across the U.S. with additional service providers that will be able to target up to 10 million consumers with diabetes.

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 28,2017

Diabetes management platform Glooko raises $35 million

Glooko, a startup selling data management healthcare service on top of a device-agnostic platform to make it easier for doctors to remotely monitor patients, has pulled in $35 million Series C funding. It had previously raised $36 million in various rounds, bringing the total up to $71 million.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Jun 28,2017

Nemaura Medical Inc. reports Full Year Financial Results

Nemaura Medical Inc. (OTC: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless disposable adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free continuous glucose monitoring (CGM) system, today reported financial results for the full year ended March 31, 2017. R&D expenses were $1,035k and $1,028k for the years ended March 31, 2017 and 2016, respectively.

View Analyst & Ambassador Comments
Go to original news
Jun 30,2017

Roche acquires mySugr to form a leading open platform for digital diabetes management

Roche (SIX: RO, ROG; OTCQX: RHHBY) and mySugr announced today that the two partners have signed an agreement under which Roche acquired all shares of mySugr GmbH. Counting more than one million users globally, mySugr is one of the leading mobile diabetes platforms in the market and will become an integral part of Roche’s new patient-centered digital health services platform in diabetes care. The acquisition allows Roche to expand its leading position in the area of diabetes management.

COLLABORATION MERGERS & ACQUISITION

#product & service

#bgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Jul 12,2017

With $18.3M in new funding, Solera Health looks beyond diabetes prevention

Solera Health, the Phoenix-based company that has created a marketplace for digital and in-person diabetes prevention programs, has raised $18.3 million in a round led by Adams Street Partners, with additional participation from Blue Cross Blue Shield Venture Partners, Sandbox Industries and SJF Ventures. The round, Solera's largest to date, brings its total funding to $30.3 million.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jul 17,2017

Novo Nordisk, Glooko team up on diabetes app

Novo Nordisk and Glooko signed a partnership in January 2017, to develop a mobile, cloud-based platform for people with diabetes to track and manage their condition, and the app syncs with data from most diabetes and exercise devices. The companies have named the solution as Cornerstones4Care Powered by Glooko, an app melding Novo Nordisk’s knowledge of diabetes and personalized patient support with Glooko’s digital platform and data analytics know-how.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES